Rabbit anti-Human MEK2 Polyclonal Antibody | anti-MAP2K2 antibody

Anti-MEK2 Antibody, Rabbit Polyclonal

Cat. Num. AAA8109382

• Reactivity: Human
• Applications: Western Blot, Immunocytochemistry, Immunofluorescence, Immunoprecipitation
• Purity: Protein A & Antigen Affinity
• Synonyms: MEK2; Polyclonal Antibody; Anti-MEK2 Antibody; Rabbit Polyclonal; MEK2/MAP2K2 Antibody; Rabbit PAb; Antigen Affinity Purified; mitogen-activated protein kinase kinase 2; Anti-CFC4 Antibody; Anti-FLJ26075 Antibody; Anti-MAPKK2 Antibody; Anti-MKK2 Antibody; Anti-PRKMK2 Antibody; anti-MAP2K2 antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Isotype: Rabbit IgG
• Specificity: Human MEK2/MAP2K2
• Purity/Purification: Protein A & Antigen Affinity
• Form/Format: Liquid; PBS, pH7.0 with 0.03% Proclin300

• Applicable Applications for anti-MAP2K2 antibody: Western Blot (WB), Immunocytochemistry (ICC), Immunofluorescence (IF), Immunoprecipitation (IP)
• Application Notes: WB: 1:2000-1:10,000; ICC/IF: 1:100-1:500; IP: 1-5uL/mg of lysate
• Immunogen: E Coli-derived Human MEK2/MAP2K2 fragment
• Conjugation: Unconjugated
• Preparation: Produced in rabbits immunized with E Coli-derived Human MEK2/MAP2K2 fragment, and purified by antigen affinity chromatography.
• Preparation and Storage: This antibody can be stored at 2-8 degree C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20 degree C to -80 degree C. Avoid repeated freeze-thaw cycles.

Western Blot (WB)

(Anti-MAP2K2 rabbit polyclonal antibody at 1:2000 dilution Lane A: Jurkat Whole Cell Lysate Lane B: HepG2 Whole Cell Lysate Lane C: HeLa Whole Cell Lysate Lane D: A549 Whole Cell Lysate Lysates/proteins at 30 ug per lane. Secondary Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. Developed using the ECL technique. Performed under reducing conditions. Predicted band size:44 kDa Observed band size:44 kDa (We are unsure as to the identity of these extra bands.))

Immunofluorescence (IF)

(Immunofluorescence staining of MAP2K2 in MCF7 cells. Cells were fixed with 4% PFA, permeabilzed with 0.1% Triton X-100 in PBS,blocked with 10% serum, and incubated with rabbit anti-Human MAP2K2 polyclonal antibody (dilution ratio 1:200) at 4 degree C overnight. Then cells were stained with the Alexa Fluor488-conjugated Goat Anti-rabbit IgG secondary antibody (green) and counterstained with DAPI (blue).Positive staining was localized to Cytoplasm.)

Immunoprecipitation (IP)

(MAP2K2 was immunoprecipitated using: Lane A:0.5 mg Jurkat Whole Cell Lysate 4 uL anti-MAP2K2 rabbit polyclonal antibody and 60 ug of Immunomagnetic beads Protein A/G. Primary antibody: Anti-MAP2K2 rabbit polyclonal antibody,at 1:100 dilution Secondary antibody: Clean-Blot IP Detection Reagent (HRP) at 1:1000dilution Developed using the ECL technique. Performed under reducing conditions. Predicted band size: 44 kDa Observed band size :47 kDa)

Related Product Information for anti-MAP2K2 antibody

Dual specificity mitogen-activated protein kinase kinase 2, also known as MAP kinase kinase 2, MAPKK2, ERK activator kinase 2, MAPK/ERK kinase 2, MEK2 and MAP2K2, is a member of the protein kinase superfamily, STE Ser/Thr protein kinase family and MAP kinase kinase subfamily. MAP2K2/MEK2 contains one protein kinase domain. MEK1 and MEK2 (also known as MAP2K1 and MAP2K2, respectively) are evolutionarily conserved, dual-specificity kinases that mediate Erk1 and Erk2 activation during adhesion and growth factor signaling. MAP2K1/MEK1 is a crucial modulator of Mek and Erk signaling and have potential implications for the role of MEK1 and MEK2 in tumorigenesis. MAP2K2/MEK2 catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. It also activates the ERK1 and ERK2 MAP kinases. Defects in MAP2K2 are a cause of Cardiofaciocutaneous Syndrome (CFC Syndrome) which is characterized by a distinctive facial appearance, heart defects, and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects, and hypertrophic cardiomyopathy.

Product Categories/Family for anti-MAP2K2 antibody

Cancer Drug Targets; Death Receptor Signaling

References

MacDonald, T.J. et al., 2001, Nat Genet. 29 (2):143-52. Mittal R., et al., 2006, Proc. Natl. Acad. Sci. USA. 103:18574-9. Narumi, Y. et al., 2007, Am J Med Genet A. 143A (8):799-807. Daub H., et al., 2008, Mol. Cell 31:438-448. Catalanotti, F. et al., 2009, Nat Struct Mol Biol. 16 (3):294-303.